Suppr超能文献

[阿昔洛韦给药所致肾衰竭。附2例报告]

[Kidney failure induced by administration of acyclovir. Apropos of 2 cases].

作者信息

Firat H, Brun P, Loirat C, Jacqz-Aigrain E

机构信息

Service de Pharmacologie Clinique, Hôpital Robert-Debré, Paris.

出版信息

Arch Fr Pediatr. 1992 Aug-Sep;49(7):641-3.

PMID:1476483
Abstract

BACKGROUND

There have been several reports of acyclovir-induced renal failure, when the drug has been administered intravenously and/or associated with water restriction.

CASE REPORT

Case n. 1: A 14 year-old boy, was treated with intravenous acyclovir because of an acute encephalitis, possibly due to Herpes viral infection. The acyclovir dose was given erroneously high, 24 mg/kg, 3 times/day, with water restriction, 30 ml/kg/day. Creatininemia increased from 70 to 200 mumol/liter after 48 hours of treatment and was 426 mumol/liter after 5 days. It decreased within a few days after the acyclovir dose was reduced to 6 mg/kg/day and the water intake was increased to 80 ml/kg/day. Case n. 2: A 17 year-old girl was suffering from chronic renal failure due to bilateral kidney hypoplasia associated with hypertension (creatinine clearance: 40 ml/min/1.73 m2). She was given intravenous acyclovir, 20 mg/kg/day, with water restriction, 30 ml/kg/day, to treat acute meningoencephalitis, possibly due to Herpes infection. Creatininemia increased from 200 to 450 mumol/l within 8 days of treatment; it returned to initial values 5 days after cessation of acyclovir and rehydration.

CONCLUSION

These 2 cases confirm the risk of renal impairment when acyclovir is administered intravenously. The risk is greater after bolus injections and when high doses are used. Water restriction is an additional risk, as was the chronic renal insufficiency in our second patient. A scheme of acyclovir therapy based on initial values of creatininemia is mandatory.

摘要

背景

有几篇关于阿昔洛韦导致肾衰竭的报道,这些报道中该药物通过静脉给药和/或与限制饮水相关。

病例报告

病例1:一名14岁男孩因急性脑炎接受静脉注射阿昔洛韦治疗,可能由疱疹病毒感染引起。阿昔洛韦剂量错误地过高,为24mg/kg,每日3次,同时限制饮水,为30ml/kg/天。治疗48小时后肌酐血症从70μmol/升升至200μmol/升,5天后为426μmol/升。在阿昔洛韦剂量降至6mg/kg/天且饮水量增至80ml/kg/天后,肌酐血症在数天内下降。病例2:一名17岁女孩因双侧肾发育不全合并高血压(肌酐清除率:40ml/min/1.73m²)患有慢性肾衰竭。她接受静脉注射阿昔洛韦,剂量为20mg/kg/天,同时限制饮水,为30ml/kg/天,以治疗可能由疱疹感染引起的急性脑膜脑炎。治疗8天内肌酐血症从200μmol/升增至450μmol/升;在停用阿昔洛韦并补液5天后恢复至初始值。

结论

这2例病例证实了静脉注射阿昔洛韦时存在肾功能损害风险。推注注射后以及使用高剂量时风险更大。限制饮水是另一个风险因素,就像我们第二个患者存在慢性肾功能不全一样。基于肌酐血症初始值的阿昔洛韦治疗方案是必需的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验